Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: argenx SE

Market Cap 48.23B 55.58B 44.46B 41.66B 77.84B 5,322B 79.46B 530B 205B 2,565B 209B 204B 8,920B P/E Ratio 2026 *
32.8x
P/E Ratio 2027 * 24.9x
Enterprise Value 43.65B 50.29B 40.23B 37.7B 70.43B 4,816B 71.9B 480B 186B 2,321B 189B 185B 8,071B EV / Sales 2026 *
8.55x
EV / Sales 2027 * 6.69x
Free-Float
100%
Yield 2026 *
0.06%
Yield 2027 * 0.11%
1 day+1.65%
1 week+6.42%
Current month+8.38%
1 month+12.21%
3 months+22.61%
6 months+2.48%
Current year+8.20%
1 week 749
Extreme 749
778.4
1 month 661.4
Extreme 661.4
778.4
Current year 568.4
Extreme 568.4
778.4
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 224.1
Extreme 224.1
810
10 years 10.55
Extreme 10.55
810
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Date Insider Type Main position Quantity % Market Cap.
11-23Sell

Director

4,680 0.0076%
11-23Fiscal year

Director

4,680 0.0076%
11-23Sell

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%+6.42%+53.16%+112.78% 54.82B
+0.03%+0.33%+49.22%+43.94% 43.27B
+3.93%-0.06%-15.10%-18.04% 21.79B
+5.27%-7.82%-1.29%+388.48% 19.92B
+0.81%-7.65%+12.35%-33.24% 15.67B
+0.53%+2.08%+8.89%-39.59% 15.26B
+1.75%+1.92%+29.13%+178.65% 13.22B
-5.27%-0.43%+87.77%+208.02% 11.58B
-1.74%+1.08%+14.99% - 11.94B
+0.23%-11.86%-33.20%+647.43% 10.13B
Average +0.72%-1.66%+20.59%+165.38% 21.76B
Weighted average by Cap. +1.13%+0.06%+28.78%+124.63%

Financials

2026 *2027 *
Net sales 5.11B 5.88B 4.71B 4.41B 8.24B 563B 8.41B 56.15B 21.74B 272B 22.09B 21.62B 944B 6.21B 7.16B 5.73B 5.36B 10.02B 685B 10.23B 68.3B 26.44B 330B 26.87B 26.29B 1,149B
Net income 1.51B 1.74B 1.39B 1.3B 2.43B 166B 2.48B 16.57B 6.41B 80.14B 6.52B 6.38B 279B 2.07B 2.38B 1.91B 1.79B 3.34B 228B 3.41B 22.74B 8.8B 110B 8.94B 8.75B 382B
Net Debt -4.59B -5.29B -4.23B -3.96B -7.4B -506B -7.56B -50.44B -19.53B -244B -19.84B -19.42B -848B -6.69B -7.71B -6.17B -5.78B -10.8B -739B -11.03B -73.6B -28.49B -356B -28.95B -28.33B -1,238B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
11/06/26 775.60 +1.65% 69,409
10/06/26 763.00 +0.66% 78,185
09/06/26 758.00 -0.68% 82,273
08/06/26 763.20 -0.37% 110,041
05/06/26 766.00 +5.10% 149,164
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
775.60EUR
Average target price
846.68EUR
Spread / Average Target
+9.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!